Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Society of America (GSA) the nation,s largest ... has chosen Barbara J. Bowers, PhD, RN, FAAN, of ... the Task Force on Minority Issues in Gerontology Outstanding ... to an individual who has exemplified outstanding commitment and ... aging. , The award presentation will take place at ...
(Date:7/29/2014)... likely to drink alcohol brands that advertise on television ... new and compelling evidence of a strong association between ... This is the conclusion of a new study from ... the Johns Hopkins Bloomberg School of Public Health and ... whether exposure to brand-specific alcohol advertising on 20 television ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Lckenhoff, PhD, of Cornell University as the 2014 recipient ... Award in Behavioral and Social Gerontology. , This distinguished ... behavioral and social gerontology. Individuals who have received their ... award is given by GSA in conjunction with the ...
(Date:7/29/2014)... Nation Homelands, NY (PRWEB) July 29, 2014 ... Indian Nation have sent a letter to Washington NFL team ... representatives that opposition to the R-word racial slur is emanating ... date, the team and Snyder have yet to respond. ... release the full text of the letter, which was first ...
(Date:7/29/2014)... The report “Filling Equipment Market by Industry (Food, ... Weight), Process (Manual, Semi-Automatic, Automatic), Product (Solid, Semi-Solid, ... to 2019”, defines the filling equipment market and ... segments with analyses and projections of the market ... of value. It also identifies the driving and ...
Breaking Medicine News(10 mins):Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Brand-specific television alcohol ads predict brand consumption among underage youth 2Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4
... in UK it has been revealed that a increase in ... way we eat over the years.,The Mental Health Foundation and ... // have led to an increase in cases of depression, ... of the most important findings of the report was a ...
... Battle against Cancer, Singer, Actress and Diva Kylie Minogue has ... ,In a statement issued this week the Singer said ... // however her treatments were still ,continuing. ,It ... in the care ,of her family and friends after her ...
... Health Inc. told the National Heritage Insurance Co., the contractor ... accepted to cover its test. ,After this the ... $2.46 to $12.41 on Nasdaq. The company prepares oncotype DX ... is taking all the responsibility to cover the medical expenses ...
... applied for a financial grant amounting to approximately 110// ... for combating tuberculosis, said the Cabinet Minister. // ... Fund on AIDS, TB and Malaria, according to the ... approximately 15 and 30 million dollars would be approved ...
... scientific and research talent in frontier areas of research ... the preferred hub for knowledge-based industries. // ... to information and communication technology alone, but spans agriculture, ... space. ,India's efforts to become a superpower ...
... of the HIV drugs in the city of Vancouver in British ... 125 as a last hope to save their lives. // Though ... study is tested on a hope to find a cure and ... ,TMC 125 is Non-nucleoside reverse transcriptase inhibitor, which has found ...
Cached Medicine News:Health News:India set to become the global knowledge hub 2Health News:India set to become the global knowledge hub 3Health News:India set to become the global knowledge hub 4
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... July 29, 2014   ... will present data from a Phase I clinical ... slow or stop Parkinson,s disease progression. The Michael J. ... grant and will discuss the impact of the results ... When:   Thursday, July 31, 2014     ...
(Date:7/29/2014)... Calif. , July 29, 2014  Drug ... amplified with rising incidence rates and the intense ... a preventative vaccine. Change is underway as the ... regimens towards highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... September 24 , - Novel Treatment ... and Reduction in Depressive Symptoms, Positive ... today at the 8th,European Congress of Epileptology, ... a novel once daily,anti-epileptic agent, significantly reduced ...
... Oral Insulin Capsule, ... on Type 1 Diabetics, JERUSALEM, Israel, September ... delivery systems, announced today that it has commenced Phase 2A,studies of ORMD ... Medical Center in Jerusalem, Israel., Oramed,s Phase 2A trial is focused ...
Cached Medicine Technology:New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 2New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 3New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 4New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 5New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 6Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: